How Personalized Is Multiple Myeloma Treatment and How Is That Changing? Introducing the Individual Risk Model for Myeloma image

How Personalized Is Multiple Myeloma Treatment and How Is That Changing? Introducing the Individual Risk Model for Myeloma

Oct 09, 2024
10:30AM - 11:30AM EDT
Online Event
Overview

As new targets and therapies are being discovered, the landscape of Multiple Myeloma treatment options is quickly evolving. How personalized are current treatment options, and how is that changing? Dr. Benjamin Diamond will join us to answer that question and give us an overview of IRMMa (Individual Risk Model for Myeloma) and it's implications for the future.

Highlights
Agenda
10:30 AM
Introductions
Cynthia Cahoon, RN

Cynthia introduces the agenda of the event and featured speaker Dr. Benjamin Diamond

10:35 AM
Presentation
Benjamin Diamond, MD

Dr. Diamond talks about the landscape of Multiple Myeloma treatment

11:05 AM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Cynthia Cahoon, RN

Cynthia Cahoon, RN

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Healthtree contact Benjamin Diamond, MD

Benjamin Diamond, MD

Dr. Diamond is a hematologist/oncologist who specializes in the treatment of plasma cell disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. His research interests include utilization of minimal residual disease (MRD)-guided approaches to clinical decision-making, maintenance therapy, and the genomics of multiple myeloma and secondary malignancies that occur in patients treated for multiple myeloma. He completed fellowship at Memorial Sloan Kettering Cancer Center, spending a year as chief fellow, and is a member of the Myeloma Genomics Laboratory at Sylvester Comprehensive Cancer Center.